Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.

The aim of the present study was to determine whether modifying the local bone environment with osteoprotegerin (OPG), the soluble decoy receptor for receptor activator of nuclear factor-kappaB (RANK) ligand, could affect tumor burden and survival in the 5T33MM murine model of multiple myeloma. Trea...

書誌詳細
主要な著者:	Vanderkerken, K, De Leenheer, E, Shipman, C, Asosingh, K, Willems, A, Van Camp, B, Croucher, P
フォーマット:	Journal article
言語:	English
出版事項:	2003

類似資料

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
著者:: Croucher, P, 等
出版事項: (2003)

Osteoprotegerin and the development of myeloma bone disease
著者:: Croucher, P, 等
出版事項: (2004)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
著者:: Croucher, P, 等
出版事項: (2001)

Bone marrow endothelial cells produce osteoprotegerin: Evidence for a role in the development of myeloma bone disease
著者:: De Leenheer, E, 等
出版事項: (2004)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
著者:: Croucher, P, 等
出版事項: (2001)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
著者:: Croucher, P, 等
出版事項: (2000)

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
著者:: Shipman, C, 等
出版事項: (2000)

Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma.
著者:: Croucher, P, 等
出版事項: (2001)

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
著者:: Croucher, P, 等
出版事項: (2003)

Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma
著者:: Croucher, P, 等
出版事項: (2002)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
著者:: Shipman, C, 等
出版事項: (2000)

Bone marrow endothelial cells express the osteoclastogenic factor RANKL and its decoy receptor OPG: Evidence for a role in the development of myeloma bone disease.
著者:: De Leenheer, E, 等
出版事項: (2002)

Bisphosphonates and in vivo models of multiple myeloma - Reply
著者:: Shipman, C, 等
出版事項: (2001)

Zoledronic acid prevents the development of myeloma bone disease and increases survival
著者:: Shipman, C, 等
出版事項: (2002)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
著者:: Shipman, C, 等
出版事項: (2002)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
著者:: Shipman, C, 等
出版事項: (2003)

Bisphosphonates--mechanisms of action in multiple myeloma.
著者:: Shipman, C, 等
出版事項: (2000)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
著者:: Shipman, C, 等
出版事項: (2002)

Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma
著者:: Mueller, G, 等
出版事項: (2004)

5T2MM murine myeloma cells and CD138+ve human myeloma cells promote osteoclastic activity rather than osteoclast formation in vitro
著者:: Mueller, G, 等
出版事項: (2004)

APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.
著者:: Croucher, P, 等
出版事項: (2002)

Role of osteoprotegerin (OPG) in cancer.
著者:: Holen, I, 等
出版事項: (2006)

Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
著者:: Holen, I, 等
出版事項: (2002)

Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma.
著者:: Clive Henry Buckle, 等
出版事項: (2012-01-01)

Mesenchymal stem cells expressing osteoprotegerin variants inhibit osteolysis in a murine model of multiple myeloma
著者:: Jerome T. Higgs, 等
出版事項: (2017-11-01)

Thymosin β4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma
著者:: Jo Caers, 等
出版事項: (2010-01-01)

Osteoprotegerin is an anti-apoptotic factor produced by prostate cancer cells that is potentially involved in tumour survival and progression.
著者:: Holen, I, 等
出版事項: (2002)

The Effects of Forodesine in Murine and Human Multiple Myeloma Cells
著者:: Liesbeth Bieghs, 等
出版事項: (2010-01-01)

The role of osteoprotegerin in breast and prostate cancer
著者:: Holen, I, 等
出版事項: (2002)

Pangasius djambal gelatin increases osteoprotegerin, decreases RANK and RANKL after tooth extraction in vivo
著者:: Fredy Mardiyantoro, 等
出版事項: (2023-12-01)

Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
著者:: Edwards, C, 等
出版事項: (2007)

Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients
著者:: Eaton, C, 等
出版事項: (2004)

The iron chelator deferoxamine decreases myeloma cell survival
著者:: Feifei Yang, 等
出版事項: (2021-01-01)

Anti-tumour activity of bisphosphonates in human myeloma cells.
著者:: Shipman, C, 等
出版事項: (1998)

Angiogenesis-Related Cytokines, RANKL, and Osteoprotegerin in Multiple Myeloma Patients in relation to Clinical Features and Response to Treatment
著者:: K. Sfiridaki, 等
出版事項: (2011-01-01)

Cells of the bone marrow microenvironment protect myeloma cells from apoptosis induced by TRAIL but not by agonists of TRAIL death receptors.
著者:: Locklin, R, 等
出版事項: (2005)

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.
著者:: Shipman, C, 等
出版事項: (1997)

Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.
著者:: Shipman, C, 等
出版事項: (2000)

Meiosis decreases recombination load; Mitosis increases recombination load
著者:: Root Gorelick, 等
出版事項: (2018-05-01)

The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
著者:: Shipman, C, 等
出版事項: (1998)